BioAge Labs (BIOA) Income towards Parent Company (2023 - 2026)
BioAge Labs (BIOA) reported Income towards Parent Company of -$22.2 million for Q1 2026, down 70.4% on a YoY basis from -$75.0 million in Q1 2025, and down 42.98% sequentially from -$15.5 million in Q4 2025.
BioAge Labs (BIOA) Income towards Parent Company (2023 - 2026) Analysis & Trends
BioAge Labs (BIOA) has 4 years of Income towards Parent Company data on file, last reported at -$22.2 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 70.4% year-over-year to -$22.2 million; the trailing twelve-month figure through Mar 2026 stood at -$91.8 million (up 35.39% YoY), and the FY2025 full-year result was -$125.9 million, down 56.33% from the prior year.
- Income towards Parent Company declined to -$22.2 million in Q1 2026, from -$15.5 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of -$11.8 million in Q3 2023 to a low of -$82.2 million in Q3 2024.
- A 4-year average of -$25.5 million and a median of -$20.3 million in 2023 frame the typical range for Income towards Parent Company.
- Across the five-year window, Income towards Parent Company slumped 597.18% in 2024 and surged 65.27% in 2025, its largest moves.
- Tracing BIOA's Income towards Parent Company over 4 years: stood at -$20.3 million in 2023, then tumbled by 53.59% to -$31.2 million in 2024, then jumped by 50.25% to -$15.5 million in 2025, then slumped by 42.98% to -$22.2 million in 2026.
- Business Quant data shows BIOA's Income towards Parent Company at -$22.2 million in Q1 2026, -$15.5 million in Q4 2025, and -$28.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.02 Bn | 32.28 Bn | 1.97 Bn |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.94 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.35 Bn | 18.54 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | BioAge Labs | 920.55 Mn | 920.55 Mn | -10.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22.21 Mn |
| Dec 31, 2025 | -15.53 Mn |
| Sep 30, 2025 | -28.55 Mn |
| Jun 30, 2025 | -25.56 Mn |
| Mar 31, 2025 | -13.03 Mn |
| Dec 31, 2024 | -31.22 Mn |
| Sep 30, 2024 | -82.20 Mn |
| Jun 30, 2024 | -15.71 Mn |
| Mar 31, 2024 | -14.03 Mn |
| Dec 31, 2023 | -20.32 Mn |
| Sep 30, 2023 | -11.79 Mn |